PPA
DFTX

Parametric Portfolio Associates’s Definium Therapeutics DFTX Stock Holding History

Parametric Portfolio Associates’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$28K Sell
1,691
-12,586
-88% -$218K ﹤0.01% 3653
2021
Q4 		$296K Buy
14,277
+5,885
+70% +$188K ﹤0.01% 3297
2021
Q3 		$293K Buy
8,392
+5,162
+160% +$223K ﹤0.01% 3311
2021
Q2 		$167K Buy
+3,230
New +$170K ﹤0.01% 3432

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $78.6M AUM 55.41% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $4.12B AUM 32.66% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Parametric Portfolio Associates's DFTX Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Definium Therapeutics (DFTX) stake by 88% in Q1 2022, selling an estimated $218K and leaving 1,691 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #3653.

Parametric Portfolio Associates first reported a position in DFTX in Q2 2021 and has held it in 4 quarters since. The position peaked at $296K in Q4 2021. 159 funds tracked by Wall St. Rank hold DFTX as of Q1 2022.

  • Parametric Portfolio Associates held 1,691 shares of Definium Therapeutics worth $28K as of Q1 2022.
  • Parametric Portfolio Associates sold 12,586 Definium Therapeutics shares in Q1 2022, an estimated $218K.
  • Definium Therapeutics made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #3653 holding.
  • Parametric Portfolio Associates first reported a position in Definium Therapeutics in Q2 2021 and has held it in 4 quarters since.
  • Parametric Portfolio Associates's Definium Therapeutics position peaked at $296K in Q4 2021.
  • 159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.